Spectrum Pharmaceuticals Announces Submission Of Non-Clinical Section Of Rolling NDA For Satraplatin

... SpectrumPharmaceuticals, Inc. (Nasdaq: SPPI) today announced that its partner, GPCBiotech AG, has submitted the non-clinical section of the rollingsubmission of a New Drug Application (NDA) to the U.S. Food and DrugAdministration (FDA) for satraplatin in combination with prednisone as asecond-line chemotherapy treatment for patients with hormone-refractoryprostate cancer (HRPC). [click link for full article] ...